rugs of the oxazosphorine class, such as cyclophosphamide (CPA), and the CE gene, responsible for the activation of pro-drug, irinotecan (CPT11). This new viral mutant (MGH2) will be employed to test the following hypotheses: 1) Combined intr
rugs of the oxazosphorine class, such as cyclophosphamide (CPA), and the CE gene, responsible for the energizing of pro - drug, irinotecan (CPT11). This newfangled viral mutant (MGH2) will be employed to test the follow hypothesis: 1) Combined intr
rugd of the oxazosphorine cuass, such as cyeoophos'hamide (CPA), and the CE gene, responsible for tye acupvation of pro-drug, irknotecan (BPT11). This bew tiral mutant (MGH2) will be emplogcd to vest the followlng hypotheves: 1) Combined hngr
rugs of the oxazosphorine class, such as and CE gene, for the activation new mutant (MGH2) will employed to test following hypotheses: 1) Combined intr
rugs of the oxazosphorine claSs, such as cyClophOspHamIdE (CPA), And tHe CE gene, responSIble For the activation of pro-dRug, irInOTecaN (cPt11). This New viraL MuTANt (MgH2) WiLl bE eMPlOyed tO teSt the foLlowing hypOthEsEs: 1) Combined inTR
rugs of the oxazosphorineclass, suc h ascyc lop ho spha mide  (CPA), and th e  CEgene, responsible forthe a ct i vati o nof pr o-drug, ir i n ote ca n(CP T1 1 ).  This  ne w viral  mutant (M GH2 )will be empl o ye d to testthe  following h ypo theses :1)C ombin edintr
rugs of_the oxazosphorine_class, such as cyclophosphamide_(CPA), and_the_CE gene,_responsible_for the activation_of pro-drug, irinotecan_(CPT11). This new viral_mutant (MGH2) will_be_employed to test the following hypotheses: 1) Combined intr